Overview
Ashley Mays-Williams, Ph.D. is a partner in the Litigation practice of Paul Hastings and is based in the firm’s New York office. Her practice primarily focuses on intellectual property law, particularly patent litigation matters in the fields of pharmaceuticals and biotechnology.
Dr. Mays-Williams has experience litigating cases arising under the Hatch-Waxman Act on behalf of innovator companies. She has represented life science companies in litigations involving pharmaceutical compounds, pharmaceutical formulations, and antibody technology. Dr. Mays-Williams has also represented and counseled clients in numerous other technology areas including medical devices, bone pastes and cements, and batteries.
Dr. Mays-Williams received her J.D. from William Mitchell College of Law, cum laude, in 2012 where she served as a member of the intellectual property law review journal Cybaris®.
She obtained her Ph.D. from King’s College London in Medical and Molecular Genetics in 2010, and graduated with a B.S. in Molecular Biology from University of Wisconsin in 2003. Prior to joining Paul Hastings, Dr. Mays-Williams was a patent prosecutor at a boutique prosecution shop located in the Midwest.
Representations
Recent representative matters include:
- Daiichi Sankyo in a hotly-contested, multi-billion dollar breach of contract intellectual property biotechnology dispute involving antibody-drug conjugates (“ADCs”) for the treatment of various cancers
- Eisai Inc. in a patent infringement case involving Targretin® (bexarotene), an oral treatment for cutaneous T-cell lymphoma
- Teijin Pharma Limited in a patent infringement case involving Uloric® (febuxostat), an oral treatment to lower blood uric acid levels
- Eli Lilly & Co. in litigation with Sanofi regarding Eli Lilly’s request to market its insulin glargine drug product Basaglar®
- Amgen Inc. in a breach of contract and business tort suit brought in the Delaware Chancery Court arising out of Amgen’s development/joint venture agreements relating to Prolia® and Xgeva®
insights
- What the Federal Circuit’s Recent Amgen v. Sanofi Decision Tells Us About the State of Enablement Law - February 19th, 2021
- California v. AbbVie—Potential Limits in the Marketing of High-Risk Drugs - October 12th, 2018
- Limitations of the Safe Harbor Defense: Lessons from Amgen v. Hospira - September 4th, 2018
- Amgen Pursues Third BPCIA Lawsuit on Newly Issued Patent - August 24th, 2018